Clinuvel Pharmaceuticals (HAM:UR9) Margin of Safety % (DCF Dividends Based): N/A (As of Jul. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:UR9 Clinuvel Pharmaceuticals Ltd HAM:UR9
80 GF Score
Price €6.00
GF Value €10.76
! 2 Warning Signs
View Full Analysis

What is Clinuvel Pharmaceuticals Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Clinuvel Pharmaceuticals's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

HAM:UR9 vs VRTX, REGN, ALNY: Margin of Safety % (DCF Dividends Based) Comparison

For the Biotechnology subindustry, Clinuvel Pharmaceuticals's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clinuvel Pharmaceuticals Margin of Safety % (DCF Dividends Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Clinuvel Pharmaceuticals's Margin of Safety % (DCF Dividends Based) falls into.


HAM:UR9
80GF Score
Clinuvel Pharmaceuticals Ltd HAM:UR9
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Clinuvel Pharmaceuticals (HAM:UR9) Overvalued in 2026?

Based on GuruFocus' analysis, Clinuvel Pharmaceuticals stock appears to be undervalued. The current stock price of €6.00 is trading 44.2% below its estimated GF Value™ of €10.76.

Key valuation signals for HAM:UR9:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: €10.76 vs. price of €6.00 (44.2% below fair value)
  • GF Score™: 80/100 with 2 warning signs

No single metric tells the full story. See the HAM:UR9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Clinuvel Pharmaceuticals Business Description

Address 535 Bourke Street, Level 22, Melbourne, VIC, AUS, 3000
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.
80GF Score

Get the complete analysis for HAM:UR9

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.00
Price
€10.76
GF Value